Off-Label Unleashed? Amarin Win Suggests Firms Still Need Strong Data To Skirt FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Court blesses combination of statements and disclosures that must accompany Vascepa promotions in a ruling that rejects FDA's narrow interpretation of 2012 Caronia case.